In the search for new therapies against cancer, immunotherapy witnessed breakthrough successes in recent years. Dendritic cells (DCs) are immune cells that are crucial for the generation of antitumor immune responses. However, the current DC-based
therapies only result in durable tumor regression in very few patients, while most patients display no clinical signs of tumor control and do not have prolonged survival, emphasizing both the shortcomings as well as the potential of these therapies.
Our team recently demonstrated that mouse and human tumors contain DC populations with anti-tumor functions, which includes an understudied DC population, namely cDC2s. Importantly, cDC2- based vaccinations reached a significant therapeutic effect in mouse models that are resistant to the currently used (immuno)therapies. Therefore, this project aims to unravel the role of cDC2s in tumors in order to assess and enhance their potential as tumor vaccines. Hereto, we will characterize mouse and human tumor-cDC2s in depth using state-of-the-art techniques and provide new tools to unravel the functions of tumor-cDC2s and to decipher their role in tumor progression.
The results of this project will provide new insights into the overlooked role of cDC2 subpopulations in tumors which might serve as a basis for novel therapeutic approaches that overcomes the currently witnessed barriers to effective therapeutic responses.
Effective start/end date1/10/1930/09/22

    Flemish discipline codes

  • Cancer biology
  • Cancer therapy

ID: 47043375